One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
US policy changes put elimination of viral hepatitis at high risk
doi : 10.1016/S2468-1253(25)00055-X
Volume 10, Issue 4, April 2025, Page 275
Early antiviral therapy in adults with moderate to highly viraemic chronic hepatitis B
Hepatitis C incidence targets among people who inject drugs: a long road ahead
Non-invasive tests for assessing liver fibrosis and cirrhosis in chronic hepatitis B
Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD
The case for reducing the use of diagnostic upper and lower gastrointestinal endoscopy
How reliable and generalisable are the results of the LASRE trial?
How reliable and generalisable are the results of the LASRE trial? – Authors' reply
Idiopathic gastroparesis consensus misses the patient's voice – Authors' reply
Pathogens don't respect politicians: US federal disruption poses a new threat to global public health
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial
[18F]fluorodeoxyglucose and [18F]fluorocholine PET-CT for staging optimisation and treatment modification in hepatocellular carcinoma (PET-HCC01): a prospective multicentre study
Global, regional, and national estimates of hepatitis C virus (HCV) infection incidence among people who inject drugs and number of new annual HCV infections attributable to injecting drug use: a multi-stage analysis
Staging liver fibrosis and cirrhosis using non-invasive tests in people with chronic hepatitis B to inform WHO 2024 guidelines: a systematic review and meta-analysis
Combination locoregional and systemic therapies in hepatocellular carcinoma
Emerging evidence-based role for external-beam radiation therapy in hepatocellular carcinoma
